The team, led by Farah H. Omer of the University of Mosul and including investigators from the University of Babylon, the University of Anbar, and Ahvaz Jundishapur University of Medical Sciences in Iran, set out to answer a deceptively simple question: what is actually swimming in the water leaving hospitals in a mid-sized Iraqi city? To find out, they passed wastewater samples through cellulose ester membrane filters, a technique that traps bacteria on the filter surface while the liquid passes through. The trapped organisms were then cultured on cetrimide agar, a selective medium that favors Pseudomonas species and produces characteristic green pigmented colonies of P. aeruginosa. Suspected colonies were identified with a VITEK2 automated system, a workhorse of clinical microbiology laboratories, and every isolate was confirmed by polymerase chain reaction targeting the ecfX gene, a species-specific genetic marker that leaves little room for misidentification.

With the isolates confirmed, the researchers turned to antibiotic susceptibility testing using the disc diffusion method, following standards set by the Clinical and Laboratory Standards Institute. The results were sobering. Resistance to aztreonam, a monobactam antibiotic often used against gram-negative infections, reached 65.5 percent of isolates, while 58.8 percent resisted ceftazidime, a third-generation cephalosporin that is a mainstay of treatment for Pseudomonas infections. Ceftazidime resistance in this species is known to be multigenic and complex, involving combinations of reduced permeability, efflux pumps, and hydrolytic enzymes, which makes its high prevalence in wastewater isolates particularly concerning. Against this grim backdrop, one drug stood out: colistin, an older polymyxin antibiotic that has been revived as a last-resort agent, inhibited 89.9 percent of the isolates, making it by far the most effective compound tested.

The most alarming statistic, however, was the burden of multidrug resistance. Using standard definitions, the team classified 82.4 percent of the isolates, 98 of the 119 recovered, as multidrug-resistant, meaning they were nonsusceptible to at least one agent in three or more antimicrobial categories. That proportion rivals or exceeds what is often reported from clinical settings, where selective pressure from therapeutic antibiotic use is intense. Its presence in wastewater implies that the hospital drain is functioning as a selective reactor: bacteria exposed to a cocktail of residual antibiotics, disinfectants, and heavy metals are winnowed down to the hardiest strains, which then multiply and disperse. Environmental microbiologists have documented similar patterns in hospital effluents in the Czech Republic, South Africa, and elsewhere, but the Iraqi data underscore how widespread the phenomenon has become and how little containment typically occurs between the hospital sink and the municipal sewer.

Resistance alone does not make a bacterium dangerous; it must also carry the tools to cause disease. The researchers therefore screened every isolate by PCR for fourteen virulence genes spanning the major weapon systems of P. aeruginosa. The results read like a catalogue of the pathogen’s most feared capabilities. The toxA gene, which encodes exotoxin A, a potent inhibitor of protein synthesis that damages host cells, was present in 100 percent of the isolates. The lasB gene, which encodes elastase B, an enzyme that degrades elastin and other tissue proteins and helps the bacterium invade and spread, was found in 65.5 percent. The exoT gene, part of the type III secretion system that injects toxic effectors directly into host cells, appeared at the same frequency of 65.5 percent. Every one of these genes contributes to the tissue destruction and immune evasion that make P. aeruginosa infections so difficult to treat in burn wounds, lungs, and catheterized patients.

The wider virulence screen painted a picture of genetically well-armed populations. Genes encoding phospholipases C (plcH and plcN), which disrupt host cell membranes; exoenzymes S, T, U, and Y, the type III secreted effectors with distinct cytotoxic and immunomodulatory roles; alkaline protease (apr); the quorum-sensing and phenazine biosynthesis genes phzI and phzII, which govern pigment production and intercellular signaling; and the alginate biosynthesis genes algD and algU, which underpin the mucoid, antibiotic-impermeable biofilm phenotype, were all detected across the collection. The simultaneous presence of exoS and exoU alleles, which are usually considered largely mutually exclusive in clinical strains, has been noted before in environmental isolates and hints that wastewater populations may recombine and shuffle virulence determinants in ways that clinical populations do not.

Perhaps the most intriguing analytical step was the search for statistical relationships between virulence genes and antibiotic susceptibility. The team reported significant positive correlations between several gene pairs and specific drugs: algU with ciprofloxacin; phzII with piperacillin; phzI with imipenem, ceftazidime, and amikacin; plcN with imipenem; plcH with amikacin, piperacillin, and piperacillin-tazobactam; exoY with piperacillin; exoT with ceftazidime; and exoS with colistin. Correlation does not establish causation, and the authors did not claim direct genetic linkage between these loci and resistance mechanisms. But such associations are consistent with a scenario in which virulence and resistance traits are being co-selected in the same bacterial lineages, whether through shared mobile genetic elements, biofilm lifestyles that favor both traits, or the linkage of virulence determinants with efflux systems that pump out antibiotics. If hospital effluent consistently selects for strains that are both drug-tolerant and toxin-armed, the public health stakes rise considerably.

The study was approved by the Ethics Committee of the University of Babylon in November 2025 and involved no human or animal samples, sidestepping many of the logistical hurdles of clinical surveillance while capturing something clinical surveillance often misses: the environmental fate of pathogens after they leave the ward. Previous work in Iraq has documented cephalosporin resistance in clinical P. aeruginosa from Basra and the presence of resistance genes in water samples from Baghdad, and studies from Iran, China, Mexico, and Bangladesh have traced resistant and virulent strains in drinking water, groundwater, soil, and food. The Babylon data fit into this global mosaic and suggest that in regions where wastewater treatment is limited or absent, hospital effluents may serve as a continuous, largely unmonitored source of high-risk bacteria entering rivers, irrigation systems, and communities.

The authors’ conclusion is blunt: hospital effluents are critical sources of multidrug-resistant and virulent P. aeruginosa, and there is an urgent demand to improve wastewater management. That demand carries technical implications. Effective interventions could include on-site pretreatment of hospital effluent before discharge, enhanced monitoring of resistance and virulence markers in sewer networks, and stewardship programs that reduce the quantity of antibiotics entering the drain in the first place. The near-universal presence of toxA and the high frequency of lasB and exoT in these environmental isolates suggest that virulence screening, not just resistance testing, should inform risk assessments of hospital wastewater. As antimicrobial resistance continues to erode the clinical arsenal, with colistin remaining one of the few reliably effective agents, the drains of the world’s hospitals have become more than plumbing. They are, according to this study, active evolutionary arenas where the next generation of dangerous pathogens may be assembling, one selective pressure at a time.

Subject of Research: Virulence genes and antibiotic resistance in Pseudomonas aeruginosa from Iraqi hospital wastewater

Article Title: Virulence arsenal and antibiotic resistance backgrounds in Pseudomonas aeruginosa isolates from hospital wastewater samples from Iraq

Article References: Omer, F. H., Al-Khafaji, N. S. K., Shakir, B., Almjalawi, A., Al-Alaq, F. T., Al-Dahmoshi, H. O. M., Al-Ouqaili, M. T. S., Ahmad, F., & Saki, M. (2026). Virulence arsenal and antibiotic resistance backgrounds in Pseudomonas aeruginosa isolates from hospital wastewater samples from Iraq. Molecular Biology Reports, 53(1), Article 1654. https://doi.org/10.1007/s11033-026-12865-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12865-w

Keywords: Pseudomonas aeruginosa, hospital wastewater, antimicrobial resistance, multidrug resistance, virulence genes, toxA, lasB, Iraq, colistin, PCR, public health, wastewater management

As professionals in the field of biomedical science understand, Pseudomonas aeruginosa is an opportunistic pathogen that primarily affects immunocompromised individuals. Its ability to acquire resistance genes, including those for metallo-β-lactamases, enables it to neutralize the effects of beta-lactam antibiotics. This characteristic escalates the urgency for alternative therapeutic strategies that can effectively address these resistant bacteria. Traditional antibiotics are showing a diminishing efficacy in treating serious infections, demanding innovative solutions such as the use of bacteriophages.

Bacteriophages, colloquially known as phages, are viruses that have evolved to infect and replicate within bacterial cells. Unlike antibiotics, which can also harm beneficial bacteria within the human microbiome, phages are specific to their bacterial targets, thereby minimizing collateral damage. This characteristic makes them a compelling candidate for therapeutic applications, especially in cases where antibiotic treatment has failed dramatically. The research conducted by Paranos and colleagues illustrates the potential of phages not just as a supplemental treatment but as a potent therapeutic option against persistent bacterial infections.

In their study published in the Journal of Biomedical Science, the researchers explored the efficacy of a unique jumbo bacteriophage against clinically isolated strains of Pseudomonas aeruginosa. This phage was chosen due to its remarkable ability to not only infect but effectively lyse antibiotic-resistant bacterial cells. The team’s results revealed promising outcomes, demonstrating that treatment with the jumbo phage could significantly reduce bacterial loads in vitro, suggesting potential therapeutic benefits for future clinical applications.

A crucial aspect of the research involved in vitro testing, which showcased the bacteriophage’s ability to infect and destroy metallo-β-lactamase producing bacteria. The study documented a substantial decrease in viable bacterial counts after phage administration, indicating a robust lytic activity against the targeted Pseudomonas aeruginosa strains. Moreover, the researchers conducted comparative analyses with conventional antibiotics, underscoring the unique advantages of phage therapy in overcoming established resistance mechanisms.

This groundbreaking research holds substantial implications for the treatment of bacterial infections globally. As healthcare systems face overwhelming numbers of drug-resistant infections, the incorporation of phage therapy could revolutionize therapeutic protocols. The successful application of bacteriophages particularly in resistant infections could lead to new treatment regimens that save lives, providing a much-needed alternative when traditional antibiotics fall short.

Furthermore, the implications of this study extend beyond the lab. The research team’s findings could pave the way for clinical trials that assess the efficacy and safety of phage therapies in human patients. The transition from bench research to clinical application is crucial as it will determine the practical viability of these bacteriophages as therapeutic agents. Regulatory pathways and large-scale production methods for phages will need to be crafted to ensure that they can be deployed effectively in medical practice.

However, the path to widespread adoption of phage therapy is not without challenges. Regulatory hurdles, public perception, funding for extensive clinical trials, and manufacturing processes all pose significant obstacles that need to be navigated. Education about the benefits and safety of phage therapy for both healthcare providers and patients will be essential to facilitate its acceptance and utilization in clinical settings.

While some might view bacteriophage therapy as a risky venture, the results from Paranos, Skliros, and Zrelovs’ work offer a compelling case for its exploration. Their patience and dedication in advancing this field of research reflect a broader movement within the scientific community aimed at developing novel solutions to overcome the rising tide of antimicrobial resistance. The findings signal a shift towards a future where bacteriophages could stand alongside traditional antibiotics, offering new hope against stubborn pathogens.

Continued research into the genetic diversity and genome structure of these jumbo bacteriophages will also play a significant role in refining their therapeutic applications. By better understanding the biology and mechanisms of action of these viruses, researchers can design more effective phage preparations tailored to target specific bacterial strains. This precision could enhance the effectiveness of phage therapy and further bolster its status as a valuable tool in the antibiotic resistance battle.

Overall, the research conducted by this innovative team provides not just evidence for the efficacy of bacteriophages in treating resistant infections, but also ignites discussions around the future of infectious disease management. As the medical community grapples with the implications of antimicrobial resistance, the promise of phage therapy shines brightly, illuminating a potential path forward for addressing one of healthcare’s most pressing challenges.

In summary, the pioneering work by Paranos and colleagues marks a significant milestone in the ongoing quest to develop effective therapies against resistant bacterial infections. Their findings reinforce the importance of continued exploration into bacteriophage biology and its clinically relevant applications, a pursuit that could redefine our approach to managing infections in an era of rising antibiotic resistance.

By addressing these urgent challenges with innovative solutions, such as the use of bacteriophages, researchers and healthcare professionals can work together to safeguard public health and improve therapeutic outcomes for patients grappling with infectious diseases.

Subject of Research: Therapeutic application of jumbo bacteriophages against metallo-β-lactamase producing Pseudomonas aeruginosa.

Article Title: Publisher Correction: Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates.

Article References: Paranos, P., Skliros, D., Zrelovs, N. et al. Environmental Conservation. J Biomed Sci 32, 105 (2025). https://doi.org/10.1186/s12929-025-01200-3

Image Credits: AI Generated

DOI:

Keywords: Bacteriophages, Antibiotic resistance, Pseudomonas aeruginosa, Metallo-β-lactamase, Phage therapy, Clinical isolates, Therapeutic application.